PFO
LFCR icon

Pathstone Family Office’s Lifecore Biomedical LFCR Stock Holding History

Pathstone Family Office’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-39,900
Closed -$388K – 1249
2020
Q3 		$388K Buy
+39,900
New +$380K 0.04% 137

Other funds holding LFCR

LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Pathstone Family Office's LFCR Position: Q4 2020 in Review

Pathstone Family Office sold out of Lifecore Biomedical (LFCR) in Q4 2020, closing a stake of 39,900 shares — an estimated $388K sold.

Pathstone Family Office first reported a position in LFCR in Q3 2020 and held it in 1 quarter. The position peaked at $388K in Q3 2020. 96 funds tracked by Wall St. Rank hold LFCR as of Q4 2020.

  • Pathstone Family Office reported no remaining Lifecore Biomedical position as of Q4 2020 after selling out during the quarter.
  • Pathstone Family Office sold 39,900 Lifecore Biomedical shares in Q4 2020, an estimated $388K.
  • Pathstone Family Office first reported a position in Lifecore Biomedical in Q3 2020 and held it in 1 quarter.
  • Pathstone Family Office's Lifecore Biomedical position peaked at $388K in Q3 2020.
  • 96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2020.

Based on Pathstone Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.